SUPERNUS PHARMACEUTICALS, INC. Adjustments to Additional Paid in Capital, Other
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Adjustments to Additional Paid in Capital, Other of $34.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2019-03-01.
Discontinued › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2019-03-01
- SUPERNUS PHARMACEUTICALS, INC. adjustments to additional paid in capital, other for the quarter ending 2013-09-30 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. adjustments to additional paid in capital, other for fiscal 2016 was $34.00K.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 9 month | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|---|---|
| 2016-12-31 | $34.00K 10-K · filed 2019-03-01 | |||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $900.00K 10-Q · filed 2013-11-13 | ||
| 2013-06-30 | $900.00K 10-Q · filed 2013-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |